Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1996 Jun;41(6):593–604. doi: 10.1046/j.1365-2125.1996.35717.x

Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline N-demethylation

JÜRGEN SCHMIDER 1, DAVID J GREENBLATT 1, JEROLD S HARMATZ 1, RICHARD I SHADER 1
PMCID: PMC2042612  PMID: 8799527

Abstract

1To determine kinetic parameters (Vmax, Km) for cytochrome P450 (CYP) mediated metabolic pathways, nonlinear least squares regression is commonly used to fit a model equation (e.g., Michaelis Menten [MM]) to sets of data points (reaction velocity vs substrate concentration). This method can also be utilized to determine the parameters for more complex mechanisms involving allosteric or multi-enzyme systems. Akaike's Information Criterion (AIC), or an estimation of improvement of fit as successive parameters are introduced in the model ( F-test), can be used to determine whether application of more complex models is helpful. To evaluate these approaches, we have examined the complex enzyme kinetics of amitriptyline (AMI) N-demethylation in vitro by human liver microsomes.

2For a 15-point nortriptyline (NT) formation rate vs substrate (AMI) concentration curve, a two enzyme model, consisting of one enzyme with MM kinetics (Vmax=1.2 nmol min−1 mg−1, Km=24 μm) together with a sigmoidal component (described by an equation equivalent to the Hill equation for cooperative substrate binding; Vmax=2.1 nmol min−1 mg−1, K′=70 μm; Hill exponent n=2.34), was favoured according to AIC and the F-test.

3Data generated by incubating AMI under the same conditions but in the presence of 10 μm ketoconazole (KET), a CYP3A3/4 inhibitor, were consistent with a single enzyme model with substrate inhibition (Vmax=0.74 nmol min−1 mg−1, Km=186 μm, K1=0.0028 μm−1).

4Sulphaphenazole (SPA), a CYP2C9 inhibitor, decreased the rate of NT formation in a concentration dependent manner, whereas a polyclonal rat liver CYP2C11 antibody, inhibitory for S-mephenytoin 4′-hydroxylation in humans, had no important effect on this reaction.

5Incubation of AMI with 50 μm SPA resulted in a curve consistent with a two enzyme model, one with MM kinetics (Vmax=0.72 nmol min−1 mg−1, Km=54 μm) the other with ‘Hill-kinetics’ (Vmax=2.1 nmol min−1 mg−1, K′=195 μm; n=2.38).

6A fourth data-set was generated by incubating AMI with 10 μm KET and 50 μm SPA. The proposed model of best fit describes two activities, one obeying MM-kinetics (Vmax=0.048 nmol min−1 mg−1, Km=7 μm) and the other obeying MM kinetics but with substrate inhibition (Vmax=0.8 nmol min−1 mg−1, Km=443 μm, K1=0.0041 μm−1).

7The combination of kinetic modelling tools and biological data has permitted the discrimination of at least three CYP enzymes involved in AMI N-demethylation. Two are identified as CYP3A3/4 and CYP2C9, although further work in several more livers is required to confirm the participation of the latter.

Keywords: cytochrome P450, amitriptyline, enzyme kinetics, Michaelis Menten equation

Full Text

The Full Text of this article is available as a PDF (434.1 KB).


Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES